The initial sensitivity of melanomas with activating BRAF mutations to BRAF inhibitors can be overcome by several mechanisms, including the compensatory upregulation of the EGFR tyrosine kinase coupled with downmodulation of the MITF and SOX10 transcription factors16,20,24,41. This evidence concerns the gene SOX10 and melanoma.